Why is Pulmozyme important?


Pulmozyme may be an essential partner in your fight against cystic fibrosis (CF)

In CF, your lungs produce extra-thick, sticky mucus. In laboratory studies, Pulmozyme made this mucus thinner and looser.

How Pulmozyme was studied

A clinical study looked at the effects of taking Pulmozyme once or twice daily. The study examined the occurrence of lung infections requiring intravenous (IV) antibiotics, and how Pulmozyme affects lung function.

The study looked at adults and children 5 years of age and older with cystic fibrosis with a forced vital capacity (FVC) greater than or equal to 40% of predicted and who were receiving standard CF treatments. 

A total of 968 patients were treated for 24 weeks:

  • 325 patients took placebo, meaning no active medicine
  • 322 patients took 2.5 mg of Pulmozyme once a day
  • 321 patients took 2.5 mg of Pulmozyme twice a day

Select Important Safety Information

Contraindications
Pulmozyme should not be used in patients who are allergic to any of its ingredients.
Please see the continued Important Safety Information below, and see the Pulmozyme full Prescribing Information for additional Important Safety Information.


Pulmozyme lowered the risk of infection

Patients on Pulmozyme once-daily experienced

Lower

27% lower risk of developing lung infections requiring IV antibiotics compared to those not taking Pulmozyme

Patients on Pulmozyme twice-daily experienced

Lower

29% lower risk of developing lung infections requiring IV antibiotics compared to those not taking Pulmozyme

Pulmozyme should not be used in patients who are allergic to any of its ingredients.


Pulmozyme showed clinically significant improvement lung function

Patients taking Pulmozyme once-daily showed:

Improvement
  • A 5.8% improvement in lung function over 6 months compared to the start of treatment
  • A 7.9% improvement in lung function within the first 8 days of starting treatment

Patients taking Pulmozyme twice-daily showed:

Improvement
  • A 5.6% improvement in lung function over 6 months compared to the start of treatment
  • A 9.0% improvement in lung function within the first 8 days of starting treatment

Cystic fibrosis patients over age 21 may benefit from twice-daily dosing to reduce the risk of lung infections requiring IV antibiotics.

Ask your doctor if twice daily is right for you. See the doctor discussion guide 


Pulmozyme is a standard part of cystic fibrosis care. More than 80% of patients with cystic fibrosis are prescribed Pulmozyme each year. If you’re just getting started on Pulmozyme, learn about financial support options.

Alert

Before taking your Pulmozyme, it is important to receive training from your CF Care Team

Tasks

Managing CF requires a multitherapy approach

Learn how each treatment makes an impact

Patients

Patient Stories

See how others are managing CF with Pulmozyme

Indication & Usage

Pulmozyme (dornase alfa) is indicated, along with standard therapies, for the management of pediatric and adult patients with cystic fibrosis (CF) to improve pulmonary function.

In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.

Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients.

Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion, and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.

Pediatric Use

The safety and effectiveness of Pulmozyme along with standard therapies for cystic fibrosis have been established in pediatric patients. The use of Pulmozyme in pediatric patients at 5 to 17 years of age is supported by evidence from a randomized, controlled trial. The use of Pulmozyme in patients less than 5 years of age is supported by the efficacy data from the same randomized, controlled trial and additional safety data in pediatric patients aged 3 months to less than 5 years who received Pulmozyme.

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

For further information, please see the Pulmozyme full Prescribing Information. If you have questions, please discuss them with your CF Care Team.